Comparative Pharmacology
Head-to-head clinical analysis: ADCIRCA versus ATMEKSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADCIRCA versus ATMEKSI.
ADCIRCA vs ATMEKSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-5 (PDE5) inhibitor; increases cGMP in pulmonary vascular smooth muscle, leading to vasodilation.
ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.
10 mg orally three times daily.
1.5 mg/kg IV every 4 weeks
None Documented
None Documented
Terminal half-life: 10–15 hours in healthy adults; prolonged in hepatic impairment (Child-Pugh B/C: up to 30 hours); clinical context: supports twice-daily dosing
Terminal elimination half-life is 12 hours; renally impaired patients have prolonged half-life up to 24 hours.
Renal: ~70% (metabolites and unchanged drug), Fecal: ~20%, Biliary: minor
Primarily renal (80% unchanged) and biliary/fecal (15% as metabolites).
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor